Steba Biotech releases positive new data for Tookad in prostate cancer

1 February 2016

Luxembourg-headquartered Steba Biotech, a privately-owned biotechnology company has announced positive top-line results from PCM304, its Latin American Phase III clinical trial of Tookad (padeliporfin di-potassium), a novel investigational treatment for localized prostate cancer and other solid tumors.

Analyses of the results showed that the primary endpoint has been met, demonstrating that Tookad increased the rate of cancer-free patients at 12 months. Quality of life parameters (urinary and erectile functions) and safety are consistent with previous Tookad clinical studies.

Tookad gets first approval in Mexico

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK